Do young, early-stage breast cancer patients with pCR to chemoimmunotherapy still benefit from PMRT?

As far as I am aware, it is not part of the usual practice to offer PMRT in the setting of T2N0 TN breast cancer. Though I think it may be considered as an "out of the box" recommendation in the setting of multiple high-risk features (larger T2 size, poor response to neo-adjuvant tx, LVI, young age,...